# Surgitron Radiolase 510(k) Summary

K992382

#### 1. Submitter Name and Address:

Frank Lin, Ph.D.
Director of R&D Engineering
Ellman International
1135 Railroad Ave.
Hewlett, NY 11557

# 2. Device Name and Classification

2.1 Device Name: Surgitron Radiolase

2.2 Classification: Class 2 Device, 21 CFR 878.4400

# 3. Description of The Device

Surgitron Radiolase is a high frequency, medium power output electrosurgical device. The design is unique, simple, energy efficiency, safe, and user friendly. Furthermore, it equips the essential operational modes that are most often used in electrosurgical application. The unit has a maximum 50 watt output power and provides the capability of precision cutting, coagulating, and hemostasis in four megacycle frequency electrical current. It is designed to comply with international safety standards.

# 4. The intended use/indication for use of the device

# 4.1. Cutting

Skin Incisions, Biopsy, Cysts, Abscesses, Tumors, Cosmetic Repairs, Development of Skin Flaps, SkinTags, Nevi, Keratosis, Oculoplastic Procedures, Blepharoplasty, Aponeurotic Repair, Levator Resection, Arthroscopic Procedures.

# 4.2. Blended Cutting and Coagulation

Skin Tags, Papilloma Keloids, Keratosis, Verrucae, Basal CellCarcinoma, Nevi, Fistulas, Epithelioma, Cosmetic Repairs, Cysts, Abscesses, Development of Skin Flaps, Oculoplastic Procedures, Arthroscopic Procedures.

#### 4.3. Hemostasis

Control of Bleeding, Epilation, Telangiectasia

# 5. Identification to predicate devices

- 5.1. Surgitron IEC with general use indication K980177
- 5.2. ERBOTOM ICC 200 with indication K933157

6. Summary of the technological characteristics of the new device in comparison to the predicate devices

Substantial Equivalence In Technological Characteristics Comparison

		SURGITRON IEC	ERBOTOM
		WITH GENERAL	ICC 200
	SURGITRON	USE INDICATION	WITH
	RADIOLASE	K980177	INDICATION
FEATURE	(NEW)*	PREDICATE	K933157
	, ,		PREDICATE
Indications For Use	Refer to Note 1 Same As New Device Same		Same As New Device
Design Specification	IEC 601-1 and 601-2-2	IEC 601-1 and 601-2-2	UL544
	The CE Aspects of	The CE Aspects of	
	Council Directive	Council Directive	
	93/42/EEC The	93/42/EEC The	
	Medical Device	Medical Device	
	Directive	Directive	
Output Energy	50 Watts	100 Watts	200 Watts
Output Waveform (s)	4.0MHz Sine-shaped,	1.7MHz, Sine-shaped	350kHz Sine-shaped
	Fully Rectified,	Fully Rectified,	1MHz
	Partially Rectified.	Partially Rectified,	Pulse-modulated
		Fulgurating-Spark-Gap	
Monopolar/Bipolar	Monopolar	Monopolar and Bipolar	Monopolar and Bipolar
Standards Met	IEC 601-1, 601-2-2,	IEC 601-1, 601-2-2,	IEC 601-1
	BSI5724:Section 2.2,	BSI5724:Section 2.2,	
	and UL2601	and UL2601	
Biocompatibity Tests	Monopolar Electrodes	Same As New Device	Same As New Device
	identical to predicate		
	device		
Sterilization Method(s)	Refer to Note II	Same As New Device	Not Indicated

<sup>\*</sup> There is no software component in this new device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 1 4 1999

Mr. Frank Lin Director of Engineering Research and Development Ellman International, Inc. 1135 Railroad Avenue Hewlett, New York 11557

Re: K992382

Trade Name: Surgitron Radiolase

Regulatory Class: II Product Code: GEI Dated: July 14, 1999 Received: July 16, 1999

Dear Mr. Lin:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

-Celia M. Witten, Ph.D., M.D.

Director

Division of General and Restorative Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

510(k) Number (if known): <u>k 992 382</u>

Device Name: SURGITRON RADIOLASE

Indication For Use: is idendical to the Surgitron as a preammendment device such as:

- \* Cutting
  Skin Incisions, Biopsy, Cysts, Abscesses, Tumors, Cosmetic Repairs, Development of
  Skin Flaps, SkinTags, Nevi, Keratosis, Oculoplastic Procedures, Blepharoplasty,
  Aponeurotic Repair, Levator Resection, Arthroscopic Procedures.
- \* Blended Cutting and Coagulation Skin Tags, Papilloma Keloids, Keratosis, Verrucae, Basal CellCarcinoma, Nevi, Fistulas, Epithelioma, Cosmetic Repairs, Cysts, Abscesses, Development of Skin Flaps, Oculoplastic Procedures, Arthroscopic Procedures.
- \* Hemostasis
  Control of Bleeding, Epilation, Telangiectasia

(PLEASE I NEEDED)	DO NOT WRITE	BELOW THIS LINE	E-CONTINUE ON ANOTHER PAGE IF
	- (1 C	Division Sign-Off) Division of General Res	ice Evaluation (ODE)  storative Devices ( 4923 82
Prescription Use _ (Per 21 CFR 801.1	09)	OR	Over-The- Counter Use(Optional Format 1-2-96)